Immunotherapies
- PDF / 169,719 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 72 Downloads / 129 Views
1 S
Immunotherapies Pancreatitis: 25 case reports
In a retrospective study, 14 women and 11 men aged between 45-85 years [specific ages and sexes not stated] treated with immune checkpoint inhibitors between 15 August 2016 and 9 January 2019, and identified from a prospectively maintained educational database of radiological immune related adverse events, developed pancreatitis while receiving immunotherapy with atezolizumab, ipilimumab, nivolumab or pembrolizumab [dosages, routes and durations of treatments to reactions onsets not stated]. The patients were receiving immunotherapy with atezolizumab (1 patient), ipilimumab and nivolumab (7 patients), nivolumab (8 patients) and pembrolizumab (9 patients). Subsequently, sixteen of the 25 patients experienced abdominal pain. In twenty-two of the 25 patients, elevated serum pancreatic enzymes were noted. Imaging findings (performed on 0–36 days of symptoms onset) revealed interstitial oedematous features, autoimmune features or interstitial oedematous with focal pancreatic duct dilatation suggestive of autoimmune feature pancreatitis. Balthazar CT severity index ranged between score of 1–2. The immune checkpoint inhibitors were withdrawn. Patients were treated with unspecified steroids, infliximab or mycophenolate mofetil. Pancreatitis resolved thereafter. Time to resolution (noted on imaging) ranged between 24–201 days. Das JP, et al. Imaging findings of immune checkpoint inhibitor associated pancreatitis. European Journal of Radiology 131: Oct 2020. Available from: URL: http:// doi.org/10.1016/j.ejrad.2020.109250
0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803504789
Reactions 3 Oct 2020 No. 1824
Data Loading...
